CADILLAC trial

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003 108(ll) 1316-23. 

Figure 4.3 Inddence of major adverse cardiac events (death, myocardial infarction, disabling stroke, or ischania-driven target vessel revascularization) at 6 months in the CADILLAC trial (34).

The development of novel and powerful antiplatelet agents has improved outcomes after PCI. In the CADILLAC trial, the use of a glycoprotein Ilb-IIIa inhibitor improved outcome in those treated with either balloon angioplasty or an intracoronary stent (21). Similarly, treatment with clopidogrel, a thienopyridine, decreases the incidence of adverse events after PCI (22,23). Neither thienopyridines nor glycoprotein Ilb-IIIa antagonists were available at the time the early trials designed to test the potential clinical efficacy of a combined approach were performed. 

Figure 4.1 Rate of TIMI 3 flow in the infarct-related artery after primary angioplasty or stent implantation in the Stent-PAMI (32) and CADILLAC (34) trials.

---